Below is a transcript of the testimonial by Dr. Michael Andreeff, from the University of Texas MD Anderson Cancer Center, about his experience publishing the paper, “Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia,” with Oncotarget.
Oncotarget is a remarkable publication.
Dr. Blagosklonny has done an outstanding job swimming against the stream because most journals that have very fast turnaround times lack good peer review, and therefore the quality of papers is not good. This is different for Oncotarget due to its editor who has previously done this for cell cycle. And, consequently, he’s publishing excellent papers that people are eager to get out for a variety of reasons.
So, I think it’s an excellent model, but it completely depends on the quality of the editor and chief. There are so many junk journals and hundreds and hundreds of new journals that have no peer review. Therefore, the publications in these journals are not only useless, but dangerous, because most of the statements are probably flawed and will never be reproduced.
I personally like this particular journal, Oncotarget, and I will certainly continue to publish there, especially data that we need to get out. For instance, for filing patents or for particular grant purposes, where we don’t want to go through peer reviews that may easily last six to 12 months.
Click here to read the full study, published by Oncotarget.
YOU MAY ALSO LIKE: More Oncotarget Videos on LabTube
Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read—without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.
For media inquiries, please contact email@example.com.